Key stats
About TC.NASDAQBIO
Home page
Inception date
Nov 13, 2018
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Capitalizes
Primary advisor
Meitav Mutual Funds Ltd.
ISIN
IL0011445264
The fund will be managed in a way that is expected to lead to the realization of its mission, achieving results derived from the rate of change in the tracking asset (see details of the tracking asset
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Government
Cash
Bonds, Cash & Other100.00%
Government83.75%
Cash11.92%
Miscellaneous4.21%
ETF0.11%
Stock breakdown by region
Middle East99.39%
North America0.61%
Latin America0.00%
Europe0.00%
Asia0.00%
Africa0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
No, TCH.F80 doesn't pay dividends to its holders.
TCH.F80 shares are issued by Meitav Investment House Ltd. under the brand Tachlit. The ETF was launched on Nov 13, 2018, and its management style is Passive.
TCH.F80 expense ratio is 1.23% meaning you'd have to pay 1.23% of your investment to help manage the fund.
TCH.F80 follows the NASDAQ Biotechnology Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
TCH.F80 invests in bonds.
TCH.F80 price has risen by 2.88% over the last month, and its yearly performance shows a −14.65% decrease. See more dynamics on TCH.F80 price chart.
NAV returns, another gauge of an ETF dynamics, showed a −2.01% decrease in three-month performance and has decreased by −16.64% in a year.
NAV returns, another gauge of an ETF dynamics, showed a −2.01% decrease in three-month performance and has decreased by −16.64% in a year.
TCH.F80 trades at a premium (2.25%) meaning the ETF is trading at a higher price than the calculated NAV.